ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinoma (2018) Feyerabend S, Boegemann M, Goebell P, Stoeckle M, Nepert D, Wride K, Thomas D, et al. Conference contribution SUNNIFORECAST - A phase II study of Nivolumab in combination with Ipilimumab versus Standard of care in advanced or metastatic non-clear cell renal cell carcinoma (2018) Scheich S, Ahrens M, Goekbuget N, Boleti E, Burkholder , Escudier BJ, Goebell P, et al. Conference contribution Complications of tracheoesophageal shunts after laryngectomy (2018) Scherl C, Kauffels J, Schützenberger A, Döllinger M, Bohr C, Koch M, Traxdorf M, Iro H Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution The role of donor clonal hematopoiesis in allogeneic hematopoietic stem cell transplantation (2018) Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Blau O, Heuser M, et al. Conference contribution Correlation of Hif1a expression of primary oral squamous cell carcinomas with histomorphologic parameters and macrophage polarization (2018) Wehrhan F, Möbius P, Amann KU, Geppert CI, Preidl R, Ries J, Neukam FW, Weber M Conference contribution Medication safety in patients treated with new oral antitumor agents: A prospective, randomized investigation on the impact of intensified clinical pharmaceutical/clinical pharmacological care on patient safety, patient knowledge and patient well-being (AMBORA). Supported by the German Cancer Aid within the Comprehensive Cancer Center Erlangen-EMN (2018) Schlichtig K, Lechner P, Grafe C, Ferstl B, Fuchs F, Hein A, Meidenbauer N, et al. Conference contribution Radiation and checkpoint Blockade in the treatment of metastases (2018) Hirschmann E, Gaipl U, Fietkau R, Distel L, Hecht M Conference contribution Predictive character of peripheral blood immunophenotype before and during treatment with PD-1 immune checkpoint inhibitors (interim analysis of the prospective phase IV ST-ICI trial) (2018) Hecht M, Harrer A, Rutzner S, Lettmaier S, Wolf W, Fietkau R, Frey B, Gaipl U Conference contribution Significance of altered PD-L1 expression in tumor tissue of oral squamous cell carcinomas (2018) Weber M, Wehrhan F, Baran C, Agaimy A, Buettner-Herold M, Preidl R, Neukam FW, Ries J Conference contribution